Clinical Trials, Phase I as Topic

"Clinical Trials, Phase I as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.

Descriptor ID	D017321
MeSH Number(s)	E05.318.760.250.500.200 N05.715.360.775.088.500.200 N06.850.520.450.250.250.200
Concept/Terms	Clinical Trials, Phase I as Topic Clinical Trials, Phase I as Topic Clinical Trials, Phase I Phase 1 Clinical Trials Phase I Clinical Trials Clinical Trials, Phase 1 Evaluation Studies, FDA Phase I Evaluation Studies, FDA Phase I Evaluation Studies, FDA Phase 1 Microdosing Trials, Human Microdosing Trials, Human Human Microdosing Trial Microdosing Trial, Human Trial, Human Microdosing Trials, Human Microdosing Human Microdosing Trials Drug Evaluation, FDA Phase I as Topic Drug Evaluation, FDA Phase I as Topic Drug Evaluation, FDA Phase I Drug Evaluation, FDA Phase 1

Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase I as Topic".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Epidemiologic Methods [E05.318]
Epidemiologic Study Characteristics [E05.318.760]
Clinical Studies as Topic [E05.318.760.250]
Clinical Trials as Topic [E05.318.760.250.500]
Clinical Trials, Phase I as Topic [E05.318.760.250.500.200]
Health Care [N]
Health Care Quality, Access, and Evaluation [N05]
Quality of Health Care [N05.715]
Health Care Evaluation Mechanisms [N05.715.360]
Epidemiologic Study Characteristics [N05.715.360.775]
Clinical Studies as Topic [N05.715.360.775.088]
Clinical Trials as Topic [N05.715.360.775.088.500]
Clinical Trials, Phase I as Topic [N05.715.360.775.088.500.200]
Environment and Public Health [N06]
Public Health [N06.850]
Epidemiologic Methods [N06.850.520]
Epidemiologic Study Characteristics [N06.850.520.450]
Clinical Studies as Topic [N06.850.520.450.250]
Clinical Trials as Topic [N06.850.520.450.250.250]
Clinical Trials, Phase I as Topic [N06.850.520.450.250.250.200]

Below are MeSH descriptors whose meaning is related to "Clinical Trials, Phase I as Topic".

Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase I as Topic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Clinical Trials, Phase I as Topic" by people in this website by year, and whether "Clinical Trials, Phase I as Topic" was a major or minor topic of these publications.

Bar chart showing 26 publications over 12 distinct years, with a maximum of 6 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
1999	0	1	1
2003	0	1	1
2004	1	2	3
2008	0	2	2
2010	2	2	4
2011	0	1	1
2013	1	1	2
2014	2	4	6
2016	1	1	2
2020	0	2	2
2022	0	1	1

Below are the most recent publications written about "Clinical Trials, Phase I as Topic" by people in Profiles.

Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022 Apr 29; 186(6):631-643.

View in: PubMed
Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD, Takahashi Y, Hasegawa S, Ming JE, DiCioccio AT, Li Y, Kovalenko P, Lu Q, Ortemann-Renon C, Ardeleanu M, Swanson BN. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2020 08; 9(6):742-755.

View in: PubMed
Pollack KE, Meneveau MO, Melssen MM, Lynch KT, Koeppel AF, Young SJ, Turner S, Kumar P, Sol-Church K, Mauldin IS, Slingluff CL. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. J Immunother Cancer. 2020 04; 8(1).

View in: PubMed
Catallozzi M, de Roche AM, Hu MC, Breitkopf CR, Chang J, Ipp LS, Francis JKR, Rosenthal SL. Adolescent and Parent Willingness to Participate in Microbicide Safety Studies. J Pediatr Adolesc Gynecol. 2017 Feb; 30(1):82-87.

View in: PubMed
Al-Hallaq HA, Chmura S, Salama JK, Winter KA, Robinson CG, Pisansky TM, Borges V, Lowenstein JR, McNulty S, Galvin JM, Followill DS, Timmerman RD, White JR, Xiao Y, Matuszak MM. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):e291-e298.

View in: PubMed
Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45.

View in: PubMed
Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.

View in: PubMed
Blumenfeld P, Pfeffer RM, Symon Z, Den RB, Dicker AP, Raben D, Lawrence YR. The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? Br J Cancer. 2014 Sep 23; 111(7):1305-9.

View in: PubMed
Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.

View in: PubMed
Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement